
We are a well-funded biotech company that is redefining drug discovery and development through our fully integrated platform. We combine ultra-high-throughput microfluidics driven functional screening, computational engineering, and translational immunology into a unified engine. Rather than approaching drug development as a series of disconnected steps, we seamlessly integrate the discovery of novel targets, functional screening of binders, computational optimization, and predictive safety assessment to develop more better and safer therapeutics. This end-to-end approach enables faster iteration, deeper biological insight, and the development of better drugs with greater precision and confidence.
We are seeking a Summer MBA Intern who will support project-based analytical work for executive leadership and cross-functional scientific teams. This role will contribute to generating insights related to oncology and autoimmune therapeutics, competitive landscapes, emerging technologies, market opportunities, and broader industry trends that help inform strategic decision-making. The intern will collaborate closely with leadership and scientific teams to contribute to targeted analyses, strategic assessments, and decision-support materials. The ideal candidate has exposure to or a strong interest in biotechnology, business strategy, market research, and understanding how scientific and commercial insights intersect in the development of innovative therapeutics.
We are open to both part-time and full-time candidates. For part-time candidates, we are open to engagement past the summer depending on business needs.
What You’ll Gain:
Responsibilities:
Skills and Qualifications:
Compensation:
Benefits:

ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8.
www.shennonbio.com